Skip to content
DataLookout
Menu

NCT06125522

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

StatusTerminated
PhasePhase 1/2
SponsorPfizer
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Reclassified as terminated (was completed) Sponsor's reason: Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.
  2. Minor Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Dec 31, 2026 to Sep 10, 2026
    • Study sites: 21 to 23
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 11 entries
    • Collaborators: 2 to 3
  3. Notable Primary and study completion dates: Apr 30, 2026 to Dec 31, 2026
    • Study sites revised (21)
    v12
  4. Minor Primary and study completion dates: Nov 4, 2025 to Apr 30, 2026
    • Study sites revised (21)
    v11
  5. Minor Primary and study completion dates: Nov 3, 2025 to Nov 4, 2025v10
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 67 to confirmed 11
    • Study sites: 47 to 21
    • Primary and study completion dates moved earlier to Nov 3, 2025
    v9
  2. Minor Site details revised at 3 of 47 sitesv8
  3. Minor Study sites: 41 to 47v7
  4. Minor Study sites: 20 to 41v6
  5. Minor Study sites: 11 to 20
    • Primary completion date: Feb 4, 2027 to Jul 23, 2026
    • Study completion date: Aug 9, 2027 to Jan 25, 2027
    v5
  6. Notable Primary completion date: Aug 3, 2026 to Feb 4, 2027
    • Study sites: 6 to 11
    • Study completion date: Feb 2, 2027 to Aug 9, 2027
    v4
  7. Notable Phase: Phase 2 to Phase 1/2
    • Study sites: 5 to 6
    v3
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 4 to 5
    • Start date changed from estimate of Nov 10, 2023 to Jan 10, 2024
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1b: Number of Participants With Dose Limiting Toxicities
Timeframe: 28 days
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Timeframe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Phase 2: Percentage of Participants With Objective Response by investigator assessment
Timeframe: Up to approximately 1 year
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Timeframe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Secondary (10)

Phase 1b, Drug drug interaction and Phase 2: Evaluation of Safety and Tolerability of ARV-471 in combination with Samuraciclib
Phase 1b: To evaluate antitumor activity of ARV-471 in combination with samuraciclib
Phase 1b and Phase 2: Duration of Response by investigator assessment.
Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.
Phase 1b and Phase 2: Progression Free Survival by investigator assessment.
Show 5 moreShow less
Phase 1b and Phase 2: Plasma concentrations of ARV-471 and samuraciclib.
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Phase 2:ctDNA plasma quantitative changes from pre-treatment
Phase 2: To evaluate the correlation between TP53 mutation status and antitumor activity
Phase 2: Overall Survival

Arms and interventions

ARV-471 in combination with SamuraciclibExperimental

ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles

Drugs: vepdegestrant, Samuraciclib

Sites

23 sites in 4 countries

United States 19, Italy 2, Belgium 1, France 1